264 related articles for article (PubMed ID: 35561071)
21. Real-World Evidence to Support the Registration of a New Osteoporosis Medicinal Product in Europe.
Davenport C; Gravel P; Wang Y; Williams SA; Wieland A; Mitlak B
Ther Innov Regul Sci; 2024 May; 58(3):505-518. PubMed ID: 38341388
[TBL] [Abstract][Full Text] [Related]
22. Food and Drug Administration vs European Medicines Agency: Review times and clinical evidence on novel drugs at the time of approval.
Joppi R; Bertele V; Vannini T; Garattini S; Banzi R
Br J Clin Pharmacol; 2020 Jan; 86(1):170-174. PubMed ID: 31657044
[TBL] [Abstract][Full Text] [Related]
23. To what degree are review outcomes aligned for new active substances (NASs) between the European Medicines Agency and the US Food and Drug Administration? A comparison based on publicly available information for NASs initially approved in the time period 2014 to 2016.
Kühler TC; Bujar M; McAuslane N; Liberti L
BMJ Open; 2019 Nov; 9(11):e028677. PubMed ID: 31772082
[TBL] [Abstract][Full Text] [Related]
24. Comparative Expedited Regulatory Programs of U.S Food & Drug Administration and Project Orbis Partners.
Hotaki LT; Shrestha A; Bennett MP; Valdes IL; Lee SH; Wang Y; Spillman D; MacAulay T; Hunt M; Gervais J; Mafi M; Panetta V; Looi YH; Shum M; Atiek E; Meincke R; Rohr UP; Ainbinder D; Boehm-Cagan A; Luxenburg O; Cerqueira MR; Mouawad LS; Thees MFRES; Prasad K; de Claro RA
Ther Innov Regul Sci; 2023 Jul; 57(4):875-885. PubMed ID: 37072651
[TBL] [Abstract][Full Text] [Related]
25. Clinical trial designs to obtain marketing authorization of drugs for haematological malignancy in Japan, the EU and the US.
Nagai S; Ozawa K
Br J Haematol; 2016 Jul; 174(2):249-54. PubMed ID: 27018163
[TBL] [Abstract][Full Text] [Related]
26. Comparison of novel oncology drugs that received dual approval from the US accelerated approval and EU conditional marketing authorisation pathways, 2006-2021: a cross-sectional study.
Xie J; Li J; Liu Y; Wang H; Wang Y; Yang Y; Chen Y; Jiang R; Shao R
BMJ Open; 2023 Jun; 13(6):e069132. PubMed ID: 37286329
[TBL] [Abstract][Full Text] [Related]
27. Therapeutic Value of Drugs Granted Accelerated Approval or Conditional Marketing Authorization in the US and Europe From 2007 to 2021.
Vokinger KN; Kesselheim AS; Glaus CEG; Hwang TJ
JAMA Health Forum; 2022 Aug; 3(8):e222685. PubMed ID: 36200635
[TBL] [Abstract][Full Text] [Related]
28. Regulatory characteristics and pivotal study design of US Food and Drug Administration approval of drugs for major vs. minor cancer.
Yamashita K; Kaneko M; Narukawa M
Eur J Clin Pharmacol; 2019 Sep; 75(9):1193-1200. PubMed ID: 31129731
[TBL] [Abstract][Full Text] [Related]
29. The association between US Food and Drug Administration-expedited review designations and health plan specialty drug coverage.
Panzer AD; Ingham M; Martin S; Chambers JD
J Manag Care Spec Pharm; 2023 May; 29(5):464-471. PubMed ID: 36989444
[No Abstract] [Full Text] [Related]
30. Oncology Products in the European Union: An Analysis of Regulatory Approvals with a CHMP Oral Explanation.
Oger A; Torqui A; Kester R; Wissink S
Ther Innov Regul Sci; 2021 Sep; 55(5):1036-1044. PubMed ID: 34041707
[TBL] [Abstract][Full Text] [Related]
31. Regulatory Review Duration and Differences in Submission Times of Drugs in the United States and Europe, 2011 to 2020.
Vokinger KN; Serra-Burriel M; Glaus CEG; Rohr UP; Hwang TJ; Dalla Torre di Sanguinetto S; Kesselheim AS
Ann Intern Med; 2023 Oct; 176(10):1413-1418. PubMed ID: 37844306
[TBL] [Abstract][Full Text] [Related]
32. Priority review drugs approved by the FDA and the EMA: time for international regulatory harmonization of pharmaceuticals?
Alqahtani S; Seoane-Vazquez E; Rodriguez-Monguio R; Eguale T
Pharmacoepidemiol Drug Saf; 2015 Jul; 24(7):709-15. PubMed ID: 26013294
[TBL] [Abstract][Full Text] [Related]
33. Analysis and comparative evaluation of expedited programs for gene therapy products: insights from the United States, the European Union, Japan, and South Korea.
Jeong H; Purja S; Kim E
Gene Ther; 2024 May; 31(5-6):242-254. PubMed ID: 38200263
[TBL] [Abstract][Full Text] [Related]
34. Post-marketing research and its outcome for novel anticancer agents approved by both the FDA and EMA between 2005 and 2010: A cross-sectional study.
Zeitoun JD; Baron G; Vivot A; Atal I; Downing NS; Ross JS; Ravaud P
Int J Cancer; 2018 Jan; 142(2):414-423. PubMed ID: 28929484
[TBL] [Abstract][Full Text] [Related]
35. Association between FDA and EMA expedited approval programs and therapeutic value of new medicines: retrospective cohort study.
Hwang TJ; Ross JS; Vokinger KN; Kesselheim AS
BMJ; 2020 Oct; 371():m3434. PubMed ID: 33028575
[TBL] [Abstract][Full Text] [Related]
36. Use of the conditional marketing authorization pathway for oncology medicines in Europe.
Hoekman J; Boon WP; Bouvy JC; Ebbers HC; de Jong JP; De Bruin ML
Clin Pharmacol Ther; 2015 Nov; 98(5):534-41. PubMed ID: 26080745
[TBL] [Abstract][Full Text] [Related]
37. Innovating by developing new uses of already-approved drugs: trends in the marketing approval of supplemental indications.
DiMasi JA
Clin Ther; 2013 Jun; 35(6):808-18. PubMed ID: 23726388
[TBL] [Abstract][Full Text] [Related]
38. Initial and supplementary indication approval of new targeted cancer drugs by the FDA, EMA, Health Canada, and TGA.
Michaeli DT; Mills M; Michaeli T; Miracolo A; Kanavos P
Invest New Drugs; 2022 Aug; 40(4):798-809. PubMed ID: 35389145
[TBL] [Abstract][Full Text] [Related]
39. Assessment of Coverage in England of Cancer Drugs Qualifying for US Food and Drug Administration Accelerated Approval.
Cherla A; Naci H; Kesselheim AS; Gyawali B; Mossialos E
JAMA Intern Med; 2021 Apr; 181(4):490-498. PubMed ID: 33616607
[TBL] [Abstract][Full Text] [Related]
40. An overview of cancer drugs approved through expedited approval programs and orphan medicine designation globally between 2011 and 2020.
Wang S; Yang Q; Deng L; Lei Q; Yang Y; Ma P; Men Y; Yung BC; Lee RJ; Zhang M; Li N
Drug Discov Today; 2022 May; 27(5):1236-1250. PubMed ID: 34971818
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
